Latest Articles
Clinical challenge of benign metastasizing leiomyoma with cardiac and hepatic involvement: A case report.
Benign metastasizing leiomyoma (BML) is a rare disorder occurring in women with a history of uterine leiomyomas and having detection of leiomyomas in extrauterine locations. This case report describes a …
Published: July 7, 2025, midnight
UFE Doesn’t Remove Fibroids–Here’s What Women Aren’t Being Told - The Malaysian Reserve
UFE Doesn’t Remove Fibroids–Here’s What Women Aren’t Being Told The Malaysian Reserve
Published: June 26, 2025, 10:51 a.m.
UFE Doesn't Remove Fibroids--Here's What Women Aren't Being Told - StreetInsider
UFE Doesn't Remove Fibroids--Here's What Women Aren't Being Told StreetInsider
Published: June 25, 2025, 10:14 a.m.
UFE Doesn't Remove Fibroids—Here's What Women Aren't Being Told - Morningstar
UFE Doesn't Remove Fibroids—Here's What Women Aren't Being Told Morningstar
Published: June 25, 2025, 10 a.m.
The global burden of polycystic ovary syndrome, endometriosis, uterine fibroids, cervical cancer, uterine cancer, and ovarian cancer from 1990 to 2021 - BMC Public Health
The global burden of polycystic ovary syndrome, endometriosis, uterine fibroids, cervical cancer, uterine cancer, and ovarian cancer from 1990 to 2021 BMC Public Health
Published: May 14, 2025, 5:32 a.m.
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - BioSpace
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids BioSpace
Published: May 7, 2025, 1:28 p.m.
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - The Manila Times
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids The Manila Times
Published: May 7, 2025, 12:24 p.m.
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - PR Newswire
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids PR Newswire
Published: May 7, 2025, noon
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - 스페셜타임스
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids 스페셜타임스
Published: May 7, 2025, noon
Uterine fibroids are a common medical condition, and for some women it can be devastating - MSN
Uterine fibroids are a common medical condition, and for some women it can be devastating MSN
Published: April 5, 2025, 7:13 p.m.
Link copied to clipboard!